The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Kennedy, Jeffrey S.Co, Mary Dawn T.
Green, Sharone
Longtine, Karen J.
Longtine, Jaclyn K.
O'Neill, Melissa A.
Adams, Janice P.
Rothman, Alan L.
Yu, Qiao
Johnson-Leva, Renita
Pal, Ranajit
Wang, Shixia
Lu, Shan
Markham, Phillip
UMass Chan Affiliations
Department of AnesthesiologyCenter for Infectious Disease and Vaccine Research
Document Type
Journal ArticlePublication Date
2008-07-01Keywords
AIDS VaccinesAdjuvants, Immunologic
Adult
Female
Human Experimentation
Humans
Hypersensitivity, Delayed
Immunization, Secondary
Male
Saponins
Skin
Vaccines, DNA
Vaccines, Subunit
Vasculitis
Life Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
This report describes the safety observations following administration of a polyvalent DNA prime-protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein+QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine.Source
Vaccine. 2008 Aug 18;26(35):4420-4. Epub 2008 Jun 25. Link to article on publisher's site
DOI
10.1016/j.vaccine.2008.05.090Permanent Link to this Item
http://hdl.handle.net/20.500.14038/39145PubMed ID
18588934Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.vaccine.2008.05.090